These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31802391)

  • 1. Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.
    Chan SJ; Stamp LK; Liebergreen N; Ndukwe H; Marra C; Treharne GJ
    Patient; 2020 Apr; 13(2):225-234. PubMed ID: 31802391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence.
    Stamp LK; Chan SJ; Marra C; Helme C; Treharne GJ
    Musculoskeletal Care; 2019 Sep; 17(3):161-169. PubMed ID: 31148375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study.
    Hazlewood GS; Loyola-Sanchez A; Bykerk V; Hull PM; Marshall D; Pham T; Barber CEH; Barnabe C; Sirois A; Pope J; Schieir O; Richards D; Proulx L; Bartlett SJ
    Rheumatology (Oxford); 2022 Feb; 61(2):606-616. PubMed ID: 33878168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
    Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
    Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.
    Lenert A; Lenert P
    Clin Rheumatol; 2017 Jan; 36(1):1-8. PubMed ID: 27896522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
    Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
    J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
    Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
    Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study.
    Currie GR; Pham T; Twilt M; IJzerman MJ; Hull PM; Kip MMA; Benseler SM; Hazlewood GS; Yeung RSM; Wulffraat NM; Swart JF; Vastert SJ; Marshall DA
    Patient; 2022 Sep; 15(5):599-609. PubMed ID: 35322390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review.
    Michielsens CAJ; van Muijen ME; Verhoef LM; van den Reek JMPA; de Jong EMGJ
    Drugs; 2021 Feb; 81(3):349-366. PubMed ID: 33453052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
    Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
    Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapering biologic DMARDs in rheumatoid arthritis.
    Braverman G; Bridges SL; Moreland LW
    Curr Opin Pharmacol; 2022 Dec; 67():102308. PubMed ID: 36274358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.
    Subesinghe S; Scott IC
    Expert Rev Clin Pharmacol; 2015; 8(6):751-60. PubMed ID: 26289226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.
    Uhrenholt L; Christensen R; Dreyer L; Hauge EM; Schlemmer A; Loft AG; Rasch M; Horn HC; Gade KH; Østgård RD; Taylor PC; Duch K; Kristensen S
    Scand J Rheumatol; 2023 Sep; 52(5):481-492. PubMed ID: 36745114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice.
    Catay E; Bravo M; Rosa J; Soriano ER
    BMC Musculoskelet Disord; 2016 Mar; 17():110. PubMed ID: 26932312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
    Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
    J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.
    Currie GR; Groothuis-Oudshoorn CGM; Twilt M; Kip MMA; IJzerman MJ; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung R; Marshall DA
    Clin Rheumatol; 2023 Aug; 42(8):2173-2180. PubMed ID: 37202606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.